MedPath

Staccato® Granisetron Multiple Dose PK

Phase 1
Completed
Conditions
Healthy
Registration Number
NCT04327765
Lead Sponsor
Alexza Pharmaceuticals, Inc.
Brief Summary

To examine the tolerability and safety of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers To characterize the pharmacokinetics of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers

Detailed Description

A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of Staccato Granisetron (AZ-010) in Healthy Volunteers

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Healthy based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit and prior to the first dose of study drug.
  • Body weight ≥ 50 kg and BMI within the range of 18 to 32 kg/m2, inclusive, at screening.
  • Negative urine tests for selected drugs of abuse and alcohol breath test at screening and Day 1.
Exclusion Criteria
  • Any significant medical condition

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Primary Outcome Measures
NameTimeMethod
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).8 days

Number of Subjects with Adverse Events as a measure of Safety and Tolerability

Secondary Outcome Measures
NameTimeMethod
Measurement of Granisetron Maximum exposure in Plasma8 days

Cmax

Measurement of Granisetron Exposure in Plasma8 days

AUC

Measurement of Granisetron Time to Maximum Exposure in Plasma8 days

Tmax

Trial Locations

Locations (1)

Celerion

🇺🇸

Tempe, Arizona, United States

Celerion
🇺🇸Tempe, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.